It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS).
His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with subtypes IBS-C and IBS-D’ (Sa607) was presented at DDW, 21-23 May 2021.
- What are the limitations of current treatments for IBS? (0:28)
- What is Blautix and what is the rationale for its use in the treatment of adults with IBS-C and IBS-D? (01:29)
- Could you tell us a little about the aims and design of the Phase II study you presented? (2:37)
- What are the efficacy and safety findings by region and what was the reason for the differences? (03:46)
Disclosures: Prof Eamonn Quigley has received research support, and acted as a consultant to 4D Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Marc Ferratnte, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Marc Ferrante, UEG 2021: Risankizumab as a Maintenance Therapy for Crohn’s Disease
Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease. His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS […]
Marc Ferrante, UEG 2021: Unmet Needs in Managing Crohn’s Disease
It was a pleasure to discuss with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) the current unmet needs in the treatment of patients with Crohn’s disease. Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!